Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biomarker

PUBLISHER: Grand View Research | PRODUCT CODE: 1433621

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1433621

Biomarkers Market Size, Share & Trends Analysis Report By Type (Efficacy, Validation), By Product, By Application (Drug Discovery & Development, Personalized Medicine), By Disease, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Biomarkers Market Growth & Trends:

The global biomarkers market size is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck's immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company's recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Report Highlights:

  • The safety segment held the largest revenue share of 37.62% in 2023 owing to the increased adoption of safety biomarkers in drug discovery and development
  • The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030 due to a rise in strategic collaborations for promoting research activities
  • The drug discovery & development segment dominated the market in 2023 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
  • The cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030. . However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
  • Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030 due to the rising investments by key players and increasing disease prevalence in the region
Show more
Product Code: 978-1-68038-979-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Application
    • 1.2.4. Disease
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for Primary Interviews in North America
      • 1.4.5.2. Data for Primary Interviews in Europe
      • 1.4.5.3. Data for Primary Interviews in Asia Pacific
      • 1.4.5.4. Data for Primary Interviews in Latin America
      • 1.4.5.5. Data for Primary Interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type and product outlook
    • 2.2.2. Application and disease outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing funding for biomarkers
      • 3.2.1.2. Increasing prevalence for chronic diseases
      • 3.2.1.3. Technological advancement
      • 3.2.1.4. Growing importance of companion diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of reimbursement policies for biomarkers
      • 3.2.2.2. High capital investment and lengthy timelines for biomarker development
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Emergence of personalized medicine
      • 3.2.3.2. Emerging economies
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Challenges associated with biomarkers validation
      • 3.2.4.2. Technical issues related to sample collection and storage
  • 3.3. Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
      • 3.3.3.1. Selling price of biomarker by top players

Chapter 4. Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Biomarkers Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Safety biomarkers
      • 4.4.1.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Efficacy biomarkers
      • 4.4.2.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Predictive biomarkers
      • 4.4.3.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Surrogate biomarkers
      • 4.4.4.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Pharmacodynamic biomarkers
      • 4.4.5.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Prognostics biomarkers
      • 4.4.6.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Validation biomarkers
      • 4.4.7.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Biomarkers Market: Product Estimates & Trend Analysis

  • 5.1. Product Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Biomarkers Market by Product Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Consumables
      • 5.4.1.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Services
      • 5.4.2.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Software
      • 5.4.3.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Biomarkers Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Diagnostics
      • 6.4.1.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.2. Drug Discovery and Development
      • 6.4.2.1. Drug discovery and development market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Personalized Medicine
      • 6.4.3.1. Personalized medicine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.4. Disease Risk Assessment
      • 6.4.4.1. Disease risk assessment market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis

  • 7.1. Disease Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Biomarkers Market by Disease Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Cancer
      • 7.4.1.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.2. Safety biomarkers
      • 7.4.1.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.3. Efficacy biomarkers
      • 7.4.1.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.4. Predictive biomarkers
      • 7.4.1.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.5. Surrogate biomarkers
      • 7.4.1.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.6. Pharmacodynamic biomarkers
      • 7.4.1.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.7. Prognostics biomarkers
      • 7.4.1.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.8. Validation biomarkers
      • 7.4.1.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2. Cardiovascular Diseases
      • 7.4.2.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.2. Safety biomarkers
      • 7.4.2.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.3. Efficacy biomarkers
      • 7.4.2.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.4. Predictive biomarkers
      • 7.4.2.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.5. Surrogate biomarkers
      • 7.4.2.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.6. Pharmacodynamic biomarkers
      • 7.4.2.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.7. Prognostics biomarkers
      • 7.4.2.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.8. Validation biomarkers
      • 7.4.2.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)Neurological Diseases
      • 7.4.3.1. Neurological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.2. Safety biomarkers
      • 7.4.3.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.3. Efficacy biomarkers
      • 7.4.3.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.4. Predictive biomarkers
      • 7.4.3.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.5. Surrogate biomarkers
      • 7.4.3.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.6. Pharmacodynamic biomarkers
      • 7.4.3.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.7. Prognostics biomarkers
      • 7.4.3.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.8. Validation biomarkers
      • 7.4.3.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4. Immunological Diseases
      • 7.4.4.1. Immunological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.2. Safety biomarkers
      • 7.4.4.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.3. Efficacy biomarkers
      • 7.4.4.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.4. Predictive biomarkers
      • 7.4.4.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.5. Surrogate biomarkers
      • 7.4.4.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.6. Pharmacodynamic biomarkers
      • 7.4.4.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.7. Prognostics biomarkers
      • 7.4.4.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.8. Validation biomarkers
      • 7.4.4.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.2. Safety biomarkers
      • 7.4.5.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.3. Efficacy biomarkers
      • 7.4.5.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.4. Predictive biomarkers
      • 7.4.5.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.5. Surrogate biomarkers
      • 7.4.5.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.6. Pharmacodynamic biomarkers
      • 7.4.5.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.7. Prognostics biomarkers
      • 7.4.5.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.8. Validation biomarkers
      • 7.4.5.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Biomarkers Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key Country Dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts for 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. F. Hoffmann-La Roche Ltd.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Abbott
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Epigenomics AG
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. General Electric
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Johnson & Johnson Services, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Thermo Fisher Scientific Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Bio-Rad Laboratories, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Siemens Healthineers AG
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. QIAGEN
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Merck KGaA
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. PerkinElmer Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Agilent Technologies, Inc.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Eurofins Scientific
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
Show more
Product Code: 978-1-68038-979-1

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 North America Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 6 North America Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 7 North America Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 8 U.S. Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 11 U.S. Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 12 Canada Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 Canada Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 16 Europe Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 21 Germany Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Germany Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 Germany Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 24 Germany Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 25 UK Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 UK Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 27 UK Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 28 UK Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 29 France Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 France Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 31 France Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 France Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 33 Spain Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Spain Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 36 Spain Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 37 Italy Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 39 Italy Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 40 Italy Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 41 Denmark Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 43 Denmark Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Denmark Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 45 Norway Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Norway Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 49 Sweden Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 51 Sweden Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 52 Sweden Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 58 Japan Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Japan Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 Japan Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 61 Japan Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 62 China Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 China Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 64 China Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 65 China Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 66 India Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 India Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 68 India Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 India Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 70 South Korea Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 71 South Korea Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 72 South Korea Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 South Korea Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 74 Australia Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 Australia Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 76 Australia Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 77 Australia Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 78 Thailand Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Thailand Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 80 Thailand Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 81 Thailand Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 82 Latin America Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 83 Latin America Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 84 Latin America Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 85 Latin America Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 87 Brazil Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Brazil Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 89 Brazil Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 90 Brazil Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 91 Argentina Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 Argentina Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 93 Argentina Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 94 Argentina Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 95 Mexico Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 96 Mexico Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 97 Mexico Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 98 Mexico Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East and Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 104 South Africa Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 South Africa Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 106 South Africa Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 107 South Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 112 Kuwait Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 113 Kuwait Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 114 Kuwait Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 116 UAE Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 117 UAE Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 118 UAE Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 119 UAE Biomarkers Market, By Disease, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary Interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary Interviews in APAC
  • Fig. 7 Primary Interviews in Latin America
  • Fig. 8 Primary Interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Biomarkers market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Biomarkers market driver impact
  • Fig. 20 Biomarkers market restraint impact
  • Fig. 21 Biomarkers market strategic initiatives analysis
  • Fig. 22 Biomarkers market: Type movement analysis
  • Fig. 23 Biomarkers market: Type outlook and key takeaways
  • Fig. 24 Safety biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 25 Efficacy biomarkers agents estimates and forecast, 2018 - 2030
  • Fig. 26 Predictive biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 27 Surrogate biomarkers estimates and forecast, 2018 - 2030
  • Fig. 28 Pharmacodynamic biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 29 Prognostics biomarkers estimates and forecast, 2018 - 2030
  • Fig. 30 Validation biomarkers estimates and forecast, 2018 - 2030
  • Fig. 31 Biomarkers market: Product movement analysis
  • Fig. 32 Biomarkers market: Product outlook and key takeaways
  • Fig. 33 Consumables market estimates and forecast, 2018 - 2030
  • Fig. 34 Services estimates and forecast, 2018 - 2030
  • Fig. 35 Software market estimates and forecast, 2018 - 2030
  • Fig. 36 Biomarkers market: Disease movement analysis
  • Fig. 37 Biomarkers market: Disease outlook and key takeaways
  • Fig. 38 Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 39 Drug discovery and development estimates and forecast, 2018 - 2030
  • Fig. 40 Personalized medicine market estimates and forecast, 2018 - 2030
  • Fig. 41 Disease risk assessment estimates and forecast, 2018 - 2030
  • Fig. 42 Others market estimates and forecast, 2018 - 2030
  • Fig. 43 Biomarkers market: Disease movement analysis
  • Fig. 44 Biomarkers market: Disease outlook and key takeaways
  • Fig. 45 Cancer market estimates and forecast, 2018 - 2030
  • Fig. 46 Cardiovascular diseases estimates and forecast, 2018 - 2030
  • Fig. 47 Neurological diseases market estimates and forecast, 2018 - 2030
  • Fig. 48 Immunological diseases estimates and forecast, 2018 - 2030
  • Fig. 49 Others market estimates and forecast, 2018 - 2030
  • Fig. 50 Global ophthalmic drugs market: Regional movement analysis
  • Fig. 51 Global ophthalmic drugs market: Regional outlook and key takeaways
  • Fig. 52 Global ophthalmic drugs market share and leading players
  • Fig. 53 North America market share and leading players
  • Fig. 54 Europe market share and leading players
  • Fig. 55 Asia Pacific market share and leading players
  • Fig. 56 Latin America market share and leading players
  • Fig. 57 Middle East & Africa market share and leading players
  • Fig. 58 North America: SWOT
  • Fig. 59 Europe SWOT
  • Fig. 60 Asia Pacific SWOT
  • Fig. 61 Latin America SWOT
  • Fig. 62 MEA SWOT
  • Fig. 63 North America, by country
  • Fig. 64 North America
  • Fig. 65 North America market estimates and forecasts, 2018 - 2030
  • Fig. 66 U.S. key country dynamics
  • Fig. 67 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 68 Canada key country dynamics
  • Fig. 69 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 70 Europe
  • Fig. 71 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 72 UK key country dynamics
  • Fig. 73 UK market estimates and forecasts, 2018 - 2030
  • Fig. 74 Germany key country dynamics
  • Fig. 75 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 76 France key country dynamics
  • Fig. 77 France market estimates and forecasts, 2018 - 2030
  • Fig. 78 Italy key country dynamics
  • Fig. 79 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 80 Spain key country dynamics
  • Fig. 81 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 82 Denmark key country dynamics
  • Fig. 83 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 84 Sweden key country dynamics
  • Fig. 85 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 86 Norway key country dynamics
  • Fig. 87 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 88 Asia Pacific
  • Fig. 89 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 90 China key country dynamics
  • Fig. 91 China market estimates and forecasts, 2018 - 2030
  • Fig. 92 Japan key country dynamics
  • Fig. 93 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 94 India key country dynamics
  • Fig. 95 India market estimates and forecasts, 2018 - 2030
  • Fig. 96 Thailand key country dynamics
  • Fig. 97 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 98 South Korea key country dynamics
  • Fig. 99 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 100 Australia key country dynamics
  • Fig. 101 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 102 Latin America
  • Fig. 103 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 104 Brazil key country dynamics
  • Fig. 105 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 106 Mexico key country dynamics
  • Fig. 107 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 108 Argentina key country dynamics
  • Fig. 109 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 110 Middle East and Africa
  • Fig. 111 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 112 South Africa key country dynamics
  • Fig. 113 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 114 Saudi Arabia key country dynamics
  • Fig. 115 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 116 UAE key country dynamics
  • Fig. 117 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 118 Kuwait key country dynamics
  • Fig. 119 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 120 Market share of key market players- Biomarkers market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!